Why the study?
Drug development and disease prevention for HF and AF are impeded by a lack of robust early-stage surrogates.
Do cardiac magnetic resonance measurements act as surrogate endpoints for the development of heart failure and atrial fibrillation?
Observational
Mendelian randomization
Do cardiac magnetic resonance measurements act as surrogate endpoints for the development of heart failure and atrial fibrillation?
Cardiac magnetic resonance measurements, such as LV ejection fraction and LV mass-to-volume ratio, may serve as robust early-stage surrogate endpoints for the development of heart failure and atrial fibrillation.
Answers are grounded in this paper and cite their sources.
Supports LV-MVR as potential HF surrogate; hypothesis-generating and requires prospective validation before practice change.
Background drug development and disease prevention of heart failure (HF) and atrial fibrillation (AF) are impeded by a lack of robust early-stage surrogates. We determined to what extent cardiac magnetic resonance (CMR) measurements act as surrogates for the development of HF or AF in healthy individuals. Methods Genetic data was sourced on the association with 22 atrial and ventricular CMR measurements. Mendelian randomization was used to determine CMR associations with atrial fibrillation (AF), heart failure (HF), non-ischemic cardiomyopathy (CMP), and dilated cardiomyopathy (DCM). Additionally, for the CMR surrogates of AF and HF, we explored their association with non-cardiac traits. Results In total we found that 10 CMR measures were associated with the development of HF, 8 with development of non-ischemic CMP, 5 with DCM, and 11 with AF. Left-ventricular (LV) ejection fraction (EF), and LV end diastolic volume (EDV) were associated with all 4 cardiac outcomes. Increased LV-MVR (mass to volume ratio) affected HF (odds ratio (OR) 0.83, 95%CI 0.79; 0.88), DCM (OR 0.26, 95%CI 0.20; 0.34), non-ischemic CMP (OR 0.44 95%CI, 0.35; 0.57). We were able to identify 9 CMR surrogates for HF and AF (including LV-MVR, biventricular EDV, right-ventricular EF, and left-atrial maximum volume) which associated with non-cardiac traits such as blood pressure, cardioembolic stroke, diabetes, and late-onset Alzheimer’s disease. Conclusion CMR measurements may act as surrogate endpoints for the development of HF (including non-ischemic CMP and DCM) or AF. Additionally, we show that changes in cardiac function and structure measured through CMR, may affect diseases of other organs leading to diabetes and late-onset Alzheimer’s disease.
No takes yet. Share an insight, caveat, or question.
Schmidt et al. (2022) conducted an observational in Healthy individuals (risk of heart failure and atrial fibrillation). Genetically predicted cardiac MRI measurements (e.g., LV-MVR) was evaluated on Development of Heart Failure (associated with increased LV-MVR) (OR 0.83, 95% CI 0.79-0.88).
Synapse has enriched 10 related papers. Consider them for comparative context: